ClinicalTrials.gg
CompletedNCT03384186Updated Aug 20, 2021

A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants

A Phase 1 interventional study of Danicopan Modified Release Prototype 1 and Danicopan Modified Release Prototype 2 in Healthy, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-20.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Mar 2018, 8 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study was to evaluate and compare the plasma pharmacokinetic profiles of ACH-0144471 (danicopan) in healthy participants after administration of single oral doses of modified release prototype formulations.

02

Conditions studied

  • Healthy

Keywords

  • Danicopan
  • ALXN2040
  • ACH-0144471
  • Pharmacokinetics
  • Modified Release
  • Factor D Inhibitor
  • Relative Bioavailability
03

In context

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • of 18.0 to 30.0 kilograms/square meter.
  • Female participants of must either agree to abstinence or use of a highly effective method of .
  • Male participants must either agree to abstinence or use of a condom plus an effective method of contraception.

Exclusion criteria

Exclusion Criteria:

  • Participants who have received any medicinal product in a clinical research study within the previous 3 months.
  • History of any drug or alcohol abuse in the past 2 years; current tobacco/nicotine user or within the last 12 months; positive drugs of abuse test result.
  • laboratory abnormalities.
  • History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder.
  • History or family history of meningococcal infection.
  • Serious adverse reaction or serious to any drug or the formulation .
  • Presence or history of clinically significant allergy requiring treatment.
  • Donation or loss of greater than 400 milliliters of blood within the previous 3 months.

Note: Other inclusion/exclusion criteria may apply, per protocol.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Danicopan Modified Release Prototype Tablets

    Participants received danicopan once each period as a single oral dose as follows: Period 1: Danicopan Modified Release Prototype 1 under fasted conditions. Period 2: Danicopan Modified Release Prototype 2 under fasted conditions. Period 3: Danicopan Modified Release Prototype 3 under fasted conditions. Period 4: Danicopan Modified Release Prototype 2 under fed conditions. There was a washout period of at least 14 days between each danicopan dosing.

    Drug: Danicopan Modified Release Prototype 1 · Drug: Danicopan Modified Release Prototype 2 · Drug: Danicopan Modified Release Prototype 3

Interventions

06

What researchers measure

Primary outcomes

  1. Time To Maximum Observed Concentration (Tmax) Of Danicopan After Treatment With Each Prototype Formulation

    Time frame: Up to 72 hours postdose

  2. Maximum Observed Concentration (Cmax) Of Danicopan After Treatment With Each Prototype Formulation

    Time frame: Up to 72 hours postdose

  3. Area Under The Concentration Versus Time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Danicopan After Treatment With Each Prototype Formulation

    Time frame: Up to 72 hours postdose

Secondary outcomes

  1. Participants Experiencing Treatment-emergent Adverse Events

    Time frame: Day 1 (postdose) through follow-up visit (10 [+/- 2] days after last study drug administration)

07

Study locations

1 site
  • Clinical Trial Site
    Ruddington, Nottingham NG111 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Mar 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2017
First posted
Dec 27, 2017
StartActual
Dec 1, 2017
Primary completionActual
Mar 21, 2018
CompletionActual
Mar 21, 2018
Last update
Aug 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03384186
Collaborators
Achillion, a wholly owned subsidiary of Alexion
Responsible party
Sponsor
First posted
Dec 27, 2017
Start date
Dec 1, 2017
Primary completion
Mar 21, 2018
Completion
Mar 21, 2018
Last update
Aug 20, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Danicopan

Start the discussion